Lewy body Dementia - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 37 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Lewy body Dementia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Lewy body Dementia - Pipeline Review, H2 2014', provides an overview of the Lewy body Dementia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lewy body Dementia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lewy body Dementia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Lewy body Dementia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Lewy body Dementia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Lewy body Dementia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Lewy body Dementia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Lewy body Dementia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Lewy body Dementia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Lewy body Dementia Overview 6
Therapeutics Development 7
Pipeline Products for Lewy body Dementia - Overview 7
Pipeline Products for Lewy body Dementia - Comparative Analysis 8
Lewy body Dementia - Therapeutics under Development by Companies 9
Lewy body Dementia - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Lewy body Dementia - Products under Development by Companies 13
Lewy body Dementia - Companies Involved in Therapeutics Development 14
Sumitomo Dainippon Pharma Co., Ltd. 14
Eisai Co., Ltd. 15
ProteoTech, Inc. 16
BioArctic Neuroscience AB 17
Varinel, Inc. 18
Lewy body Dementia - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 25
Drug Profiles 27
donepezil hydrochloride - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
zonisamide - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
PD-61W3 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
VAR-10100 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
IIPP-1 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
PD-61-W3 Backup - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
PD-0805 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Lewy body Dementia - Recent Pipeline Updates 34
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37

List of Tables
Number of Products under Development for Lewy body Dementia, H2 2014 7
Number of Products under Development for Lewy body Dementia - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Lewy body Dementia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 14
Lewy body Dementia - Pipeline by Eisai Co., Ltd., H2 2014 15
Lewy body Dementia - Pipeline by ProteoTech, Inc., H2 2014 16
Lewy body Dementia - Pipeline by BioArctic Neuroscience AB, H2 2014 17
Lewy body Dementia - Pipeline by Varinel, Inc., H2 2014 18
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Stage and Target, H2 2014 21
Number of Products by Stage and Mechanism of Action, H2 2014 23
Number of Products by Stage and Route of Administration, H2 2014 24
Number of Products by Stage and Molecule Type, H2 2014 26
Lewy body Dementia Therapeutics - Recent Pipeline Updates, H2 2014 34